What one share of Whitehawk Therapeutics holds
We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.
Whitehawk Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.10 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.96 |
| Cash and investments | $1.50 |
| Book value | $3.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $5.51 | −$1.76 | $0.01 | −$5.00 | — | −$4.89 |
| 2021 | $1.57 | −$12.41 | $0.01 | −$2.52 | — | — |
| 2022 | $0.68 | −$2.69 | $0.02 | −$2.22 | — | $6.48 |
| 2023 | $0.90 | −$2.44 | $0.15 | −$2.36 | — | $4.28 |
| 2024 | $0.96 | −$2.36 | $0.06 | −$2.26 | — | $2.13 |
| 2025 | $0.12 | −$0.33 | $0.01 | −$1.58 | — | $2.89 |
Common questions about Whitehawk Therapeutics
How much does one share of Whitehawk Therapeutics earn?
Over the last 12 months, Whitehawk Therapeutics lost $1.10 for each share.
Does Whitehawk Therapeutics pay a dividend?
Whitehawk Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Whitehawk Therapeutics’s book value per share?
Whitehawk Therapeutics’s book value is $3.21 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Whitehawk Therapeutics have?
Each share of Whitehawk Therapeutics has $1.50 of cash and investments, as of June 30, 2026.
What is Whitehawk Therapeutics’s free cash flow per share?
−$0.96 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Whitehawk Therapeutics bought back shares?
Whitehawk Therapeutics’s share count rose about 2334% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.